Brief: Sana Biotechnology Obtains Exclusive License From National Institutes Of Health For CD22 Car Construct
11/01/2022 11:10
Jan 11 (Reuters) - Sana Biotechnology Inc SANA.O :
* SANA BIOTECHNOLOGY OBTAINS EXCLUSIVE LICENSE FROM NATIONAL INSTITUTES OF
HEALTH
FOR CD22 CAR CONSTRUCT
* SANA BIOTECHNOLOGY INC - SANA AGREED TO PAY NIH AN UPFRONT AMOUNT, CERTAIN
MILESTONE PAYMENTS
Source text for Eikon: ID:nGNX19K1Lx
Further company coverage: SANA.O
Recent news on Sana Biotechnology
See all newsSana Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary
Sana Biotechnology Q2 adjusted loss narrows, beats estimates
Brief: Sana Biotechnology Q2 Adjusted EPS USD -0.13 Vs. IBES Estimate USD -0.15
Sana Biotechnology posts Q1 adjusted loss narrower than expected, extends cash runway
Brief: Sana Biotechnology Q1 Adjusted EPS USD -0.14 Vs. IBES Estimate USD -0.17